Bullous pemphigoid is a chronic autoimmune skin disorder that cause generalized, pruritic, bullous lesions in elderly patients. Bullous pemphigoid occurs more often in patients aged 60 years and above, but can also occur in children. IgG autoantibodies bind to certain hemidesmosomal antigens (BPAg1, BPAg2), resulting in the activation of complement system to form a sub epidermal blister. The exact cause of bullous pemphigoid is unknown. However, some of the risk factors that may trigger the disease include drugs (including furosemide, spironolactone, sulfasalazine, penicillin, penicillamine, etanercept, and antipsychotics), physical triggers (including trauma, radiation therapy for breast cancer, UV radiation, and anthralin), skin disorders (including psoriasis, lichen planus, and some infections), diabetes mellitus, rheumatoid arthritis, ulcerative colitis, and genetic and environmental factors may also play a role. Diagnosis of bullous pemphigoid occurs by skin biopsy and immunofluorescence testing of skin and serum. The aim of bullous pemphigoid treatment is to stop new blisters forming and heal the blisters that are already there. Topical and systemic corticosteroids are used initially. The drug candidates in the pipeline of bullous pemphigoid include, but are not limited to, Ligelizumab, Bertilimumab and NPB-01.
Some of the companies having drugs in the bullous pemphigoid pipeline include iCo Therapeutics Inc., Immungenetics AG, and TxCell SA.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licencing, grants, technology and others.